Aquestive Therapeutics Stock Discussion

$Aquestive Therapeutics (AQST.US)$
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics (NASDAQ: AQST) announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ sublingual film. The study met both primary and secondary endpoints, demonstrating rapid symptom resolution beginning two minutes after administration. The median time for...

$Aquestive Therapeutics (AQST.US)$ Reuters· 1 min ago
Aquestive Therapeutics Inc - Oas Challenge Study Meets Primary and Secondary Endpoints

$Aquestive Therapeutics (AQST.US)$ the monopoly has been going for long enough.

$Aquestive Therapeutics (AQST.US)$ ownership is 5.99% they see the value in the company as much as we do. FDA approval, production and distribution will significantly increase value. Plus, eliminate PFIZER monopoly in market l.

$Aquestive Therapeutics (AQST.US)$ Buy the dips and hold... Just short sales driving the price down.

$Aquestive Therapeutics (AQST.US)$ 👀

$Aquestive Therapeutics (AQST.US)$
Top of cloud bounce would like it break the 4.39 Resistance/ Above 4.4 Tenkan Sen. Once Broken target 4.98 then 6.08.

$Aquestive Therapeutics (AQST.US)$
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
Aquestive Therapeutics (NASDAQ: AQST) has commented on the FDA's recent approval of the first non-injection-based epinephrine device for treating severe allergic reactions, including anaphylaxis. The company views this as a positive development for patients seeking altern...